1910
+71%
est. 2Y upside i
Multimodal AI Platform for Modality Agnostic Drug Discovery™
Rank
#908
Sector
Biotechnology
Est. Liquidity
~4Y
Data Quality
Data: Medium1910 offers high upside potential (71% expected return) but with significant risk from incumbent competition and capital needs.
Last updated: July 3, 2026
AI drug design leadership drives sustained high multiple (12x) with IPO window opening, implying ~$516M exit value; after dilution and preference, common stock returns ~200%.
Revenue grows to $43M; exit multiple converges to 7.5x (midpoint of comps) for $322.5M exit; after dilution and preference, common stock returns ~126%.
Competitive pressure from incumbents compresses multiple to 3x, yielding $129M exit below entry valuation; after preference and dilution, common stock loses ~29%.
Preference Stack Risk
highFunding Intensity
29%1x non-participating preferred on $40M total funding; common stock faces 28.6% preference overhang on entry valuation.
Dilution Risk
highLikely additional funding rounds given capital intensity and early stage; assumed 20% dilution over 2 years.
Secondary Liquidity
moderateSecondary market trades at $140M imply active but limited liquidity.
Questions to Ask at the Interview
Strategic questions based on 1910's data — designed to show you've done your homework.
- 1
“How does 1910's AI platform differ from Isomorphic Labs' approach?”
- 2
“What are the key milestones in the next 2 years to justify the valuation?”
- 3
“What is the expected timeline to profitability and how will additional funding rounds affect equity?”
Community
Valuation Sentiment
Our model estimates +71% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.